

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

6248.8

Serial No.

11002 U.S. PTO
10/055663
03/23/03**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicants

Erik H.F. Wong et al.

Filing Date

01-23-2002 (Herewith)

Group

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
WJ	4,229,449	10-21-80	Melloni <i>et al.</i>	424	248.58	
	4,596,807	06-24-86	Crosby	514	277	
	5,068,433	11-26-91	Melloni <i>et al.</i>	564	349	
	5,391,735	02-21-95	Melloni <i>et al.</i>	544	174	
	6,028,070	02-22-00	Heiligenstein	514	238.8	09-23-97
	6,046,193	04-04-00	Hieligenstein	514	239.2	09-17-98

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
WJ	2,014,981	09-05-79	Great Britain				
	2,167,407	05-11-88	Great Britain				
	WO 96/12485	05-02-96	PCT				
	WO 97/35584	10-02-97	PCT				
	WO 97/35586	10-02-97	PCT				
	WO99/15163	04-01-99	PCT				
	WO99/15176	04-01-99	PCT				
	WO99/15177	04-01-99	PCT				
	WO 99/20279	04-29-99	PCT				
	WO 99/52531	10-21-99	PCT				

EXAMINER

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

6248.8

Serial No.

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*

Applicants

Erik H.F. Wong et al.

Filing Date

01-23-2002 (Herewith)

Group

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
257	WO 99/52518	10-21-99	PCT				
2	WO 99/58130	11-18-99	PCT				
	WO 01/26623	04-19-01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

257	J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders : A Review of Supporting Evidence, Am. J. of Psychiatry, Vol. 122, pp. 509-22 (Nov. 1965).
	T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: a-Receptor Mediation, Science, Vol. 202, pp. 1089-91 (1978):
	E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block Norepinephrine Uptake, Europ. J of Pharmacology, Vol. 104 pp. 277-86 (1984).
	C.B. Nemeroff, The Neurobiology of Depression, Scientific American (1988) (8 pages).
	M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., Vol. 1, no. 4, pp. 243-53 (1989).
	T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, Vol. 350, no. 28, pp. 350-56 (March 1991).
	M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, Vol. 45, pp. 3-9 (1991).
	E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, Vol. 52, no. 6 Suppl., pp. 4-10 (June 1991).
V	M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., Vol. 326, No. 19, pp. 1250-56 (1992).

EXAMINER

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

6248.8

Serial No.

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*

Applicants

Erik H.F. Wong et al.

Filing Date

01-23-2002 (Herewith)

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Psychopharmacology, Vol. 114, pp. 559-65 (1994).

M. Max, "Treatment of Post-Herpetic Neuralgia: Antidepressants," Ann. Neurol., Vol. 35, Suppl., pp. s50-s53 (1994).

W. Reimann et al., "Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol," Biochem. Pharmacol., Vol. 47, No. 12, pp. 2289-93 (1994).

C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Against Repeated Oral Doses and Lack of Enzymatic Alterations, Biopharm. Drug Dispos. Vol. 17, No. 7, pp. 623-33 (1996).

R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Chapter 19, pp. 431-39, (1996)

B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S11-S16 (1997).

Discussion, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S71-S73 (1997).

S.A. Montgomery, Is There a Role For a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S3-S9 (1997).

S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Patient, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).

I. Hindmarch, The Effects of Antidepressants on Psychomotor Function With Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, Vo. 7, Suppl. 1, pp. S17-S21 (1997).

E. Frigerio et al., Pharmacokinetics of Reboxetine Enantiomers in the Dog, Chirality, Vol. 9, pp. 303-06 (1997).

A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, Vol. 17, no. 2, Suppl. 1, pp. 2S-18S (1997).

B. E. Leonard, The Role of Noradrenaline in Depression: a Review, J. Psychopharmacology, Vol. II, no. 4 Suppl., pp. S39-S47 (1997).

EXAMINER

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

6248.8

Serial No.

INFORMATION DISCLOSURE STATEMENT*(Use several sheets if necessary)*

Applicants

Erik H.F. Wong et al.

Filing Date

01-23-2002 (Herewith)

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

259	Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, a Selective Noradrenaline Reuptake Inhibitor," Euro. Neuropsychopharmacol., Vol. 7, Suppl. 1, pp. s23-s35 (1997).
1	M. Owens et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites," J. Pharmacol. Exp. Ther., Vol. 283, pp. 1305-1322 (1997).
	D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, Vol. 51, pp. 313-22 (1998).
	Anonymous, Reboxetine – Another New Antidepressant, Drugs and Therapeutics Bull., 36 (11) (1998).
	S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, Vol. 59, Suppl. 14, pp. 26-29 (1998).
	G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).
	J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, Vol. 59, Suppl 14, pp. 8-10 (1998).
	A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination With Sertraline in an Animal Model of Depression, Eur. J. of Pharmacology, pp. 1-10 (1998).
	J. Massana et al., Reboxetine: A Double-Blind Comparison With Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, Vol. 14, No. 2, pp. 73-80 (1999).
	J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm. Drug Dispos. Vol. 20, no. 1, pp. 53-57 (1999).
	K. Moore et al., "Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality," Am. J. of Forensic Med. and Path., Vol. 20, No. 1, pp. 98-100 (1999).
✓	S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, International Clinical Psychopharmacology, Vol. 14, Suppl. 1, pp. S27-S31 (May 1999).

EXAMINER



WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

3/23/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6248.8	Serial No.
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Erik H.F. Wong et al.	
		Filing Date 01-23-2002 (Herewith)	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	International Search Report in PCT/US00/17256 dated July 12, 2001.
	International Preliminary Examination Report in PCT/US00/17256 dated December 19, 2001.

@PFDesktop\ODMA/PCDOCS/DOCS/547883/1

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED	3/23/03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



TECH CENTER 1600/2900

MAY 10 2002

RECEIVED

Substitute for form 1449/PTO (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/055,663
				Filing Date	January 23, 2002
				First Named Inventor	Wong et al.
				Art Unit	1614
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	6248.8

U.S. PATENT DOCUMENTS				
Examiner Initials*	Document Number	Publication Date	Name of Patentee or Applicant	
	Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	
209 ↓	5,192,751	03-09-1993	Thor	
	5,281,624	01-25-1994	Gehlert et al.	
	5,441,985	08-15-1995	Foreman	
	5,744,474	04-28-1998	Thor	
	5,922,914	07-13-1999	Gage et al.	
	5,998,430	12-07-1999	Schwantes et al.	
	6,028,070	02-22-2000	Heiligenstein	
	6,066,643	05-23-2000	Perry	

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Patent Document	Publication Date	Name of Patentee or	
	Country Code-Number-Kind Code (if known)	MM-DD-YYYY	Applicant of Cited Document	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
209	J. Mark Ruscin and Nora E. Morgenstern, "Tolterodine Use for Symptoms of Overactive Bladder," The Annals of Pharmacotherapy, Abstract Vol. 33, pgs. 1073-82 (October 1999).	

Examiner Signature	WILLIAM R. A. JARVIS PRIMARY EXAMINER	Date Considered	3/23/03
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.